An observational study in Liver Cancer, Esophageal Cancer and Colorectal Cancer, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by University of Colorado, Denver · Observational
Among 566 studies in Liver Neoplasms with a site in United States — 83 open to participants now, 122 under way, 6 of them phase 3. Liver Neoplasms · United States.
Among the 566 studies in Liver Neoplasms with a site in United States, this one is the 47th largest by planned enrollment of the 111 observational ones that give a count, is one of 22 that started in 2022, is one of 111 observational ones, reaches primary completion later than 87 of the 119 other live ones, and was the 485th registered.
1,345 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
Browse Liver Neoplasms studies →83 of the 566 studies in Liver Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
University of Oklahoma · Sites in United States
Ages 18+
Melissa Lumish · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 244 Liver Neoplasms studies recruiting now, 138 (57%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
566 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 189 · Phase 2 178 · Phase 3 29 · Phase 4 13
First in 1992; this study’s year is marked. 22 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 342 observational studies indexed under Liver Neoplasms.
Median enrollment 30 across the 433 interventional studies, 143 across the 111 observational. Of the 398 that completed or were terminated, 144 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 566 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
University of Colorado, Denver has 3 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Liver Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02523443Phase 3Memorial Sloan Kettering Cancer CenterPatient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection | 2027-08 |
| NCT04390724Northwestern UniversityOptimizing Y90 Therapy for Radiation Lobectomy | 2026-11-27 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT07044362Case Comprehensive Cancer CenterHistotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | 2026-12-01 |
Among the 566 studies in Liver Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.
Aim 1: Evaluate the correlation between pre-operative TEG parameters and disease burden in patients with a new diagnosis of hepatopancreaticobiliary, esophageal, colorectal, and lung adenocarcinoma vs controls with no known malignancy.
Aim 2: Explore if pre- and post-operative TEG parameters vs routine clinical coagulation parameters (platelet count, prothrombin time [PT], partial thromboplastin time [PTT]) are predictive of pre- and post-operative thrombotic (deep vein thrombosis [DVT], pulmonary embolism [PE], stroke, myocardial infarct [MI]) and hemorrhagic complications.
Aim 3: Evaluate if correction of TEG parameters after surgery is predictive of curative resection and if the failure of TEG parameters to correct after surgery or chemoradiothearpy is predictive of cancer recurrence and overall survival.
Aim 4: Perform proteomic analyses on the tumor microenvironment of cancer tissue samples to investigate whether tumor histology and protein composition is associated with specific TEG derangements that have been previously correlated to poor outcomes, potentially identifying a specific subtype of pancreatic cancer.
Patients who are evaluated at the University of Colorado Cancer Center with a new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma
Diagnostic Test: TEG indices
Patients undergoing major surgery
Diagnostic Test: TEG indices
Blood samples
Also known as: Control
TEG indices of coagulation
R time (minutes \~ coagulation factors), angle (degrees \~ fibrinogen function), MA (mm \~ platelets function), and LY30 (%\~ fibrinolysis) measured at baseline (initial presentation or time of diagnosis), after neoadjuvant chemotherapy (if applicable), pre-operatively (before the induction of general anesthesia), intra-operatively (after tumor removal), post-operative days 1, 3 and 5, and at routine follow up appointments at 2 weeks, 3 months, 6 months and 1 year after surgery.
Time frame: One Year
Disease burden as measured by TNM staging
Disease burden as measured by TNM staging
Time frame: One year
Pre- operative thrombotic and hemorrhagic complications.
Pre-operative thrombotic and hemorrhagic complications.
Time frame: One Year
Recurrence free and overall survival.
Recurrence free and overall survival.
Time frame: One Year
Proteomic analysis of intro-operative sample tumor microenvironment
Proteomic analysis of intro-operative sample tumor microenvironment
Time frame: One Year
Post-operative thrombotic and hemorrhagic complications
Post-operative thrombotic and hemorrhagic complications
Time frame: One Year
Tumor Type
Benign, pre-malignant, malignant
Time frame: One Year
Number of patients with pre-operative nodal
Benign, pre-malignant, malignant
Time frame: One Year
Number of patients withneuronal invasion
neuronal invasion
Time frame: One year
Number of patients with mass resectability
mass resectability
Time frame: One year
Number of patients withcomplete pathologic resection
complete pathologic resection
Time frame: one year
Number of patients withsurgical margins
surgical margins
Time frame: One year
blood transfusion requirements
Number of patients withblood transfusion requirements
Time frame: One Year
pre-operative distant metastasis
Number of patients withpre-operative distant metastasis
Time frame: One year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for May 2028, 71 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 71 months is below that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →